Greg MacMichael, Ph.D., joins Cook Pharmica as Vice President of Development, CSO
September 22, 2008
Bloomington, IN, September 22, 2008 – Greg MacMichael, Ph.D. has joined Cook Pharmica, the global biopharmaceutical contract development and manufacturing division of Cook Medical, as vice president of development and chief scientific officer.
With 25 years of biopharmaceutical experience, MacMichael has worked with a variety of notable companies including Eli Lilly, Chiron and Centocor. Most recently MacMichael served as vice president of Vaccine Development at Wyeth, where he was instrumental in the development of Prevnar, Prevnar 13 and CAIV (Cold Adapted Influenza Vaccine). His background includes development of cell culture processes, recombinant protein, antibody and vaccine therapies as well as commercialized bioprocess operations.
MacMichael has been responsible for multiple pilot plants and full scale CGMP manufacturing facilities for both bulk drug substance and final drug product. This broad range of knowledge will be beneficial to Cook Pharmica's clients as the company expands its current active pharmaceutical ingredient (API) manufacturing facility to include formulation, filling and finishing of parenteral products.
“Greg not only has the scientific expertise but he also has extensive experience with CGMP-compliant scale-up and production,” said Cook Pharmica president Jerry Arthur. “This knowledge will provide a strong foundation from which he can lead our process development scientists. We are proud to have him join our team.”
About Cook Pharmica:
Cook Pharmica (www.cookpharmica.com) is a biopharmaceutical contract development and manufacturing organization (CDMO) manufacturing mammalian cell culture-based pharmaceuticals for pre-clinical through commercial use. Cook Pharmica also offers cell line/strain development, clone selection, cell line adaptation, media optimization, process development, analytical development, cell banking/storage, stability testing/storage and regulatory submission support, and will be offering parenteral contract filling and finishing in early 2010.
About Cook Medical:
Cook Medical was one of the first companies to help popularize interventional medicine, pioneering many of the devices now commonly used worldwide to perform minimally invasive medical procedures. Today, the company integrates minimally invasive medical device design, biopharma, gene and cell therapy, and biotech to enhance patient safety and improve clinical outcomes in the fields of aortic intervention; interventional cardiology; critical care medicine; gastroenterology; radiology, peripheral vascular, bone access and oncology; surgery and soft tissue repair; urology; and assisted reproductive technology, gynecology and high-risk obstetrics. Founded in 1963 and operated as a family-held private corporation, Cook is a past winner of the prestigious Medical Device Manufacturer of the Year Award from Medical Device & Diagnostic Industry magazine. For more information, visit www.cookmedical.com.